Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Payables (2021 - 2025)

Historic Payables for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $49.8 million.

  • ARS Pharmaceuticals' Payables rose 20124.08% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.8 million, marking a year-over-year increase of 20124.08%. This contributed to the annual value of $22.8 million for FY2024, which is 96039.93% up from last year.
  • ARS Pharmaceuticals' Payables amounted to $49.8 million in Q3 2025, which was up 20124.08% from $44.3 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Payables' 5-year high stood at $49.8 million during Q3 2025, with a 5-year trough of $126000.0 in Q3 2022.
  • Over the past 5 years, ARS Pharmaceuticals' median Payables value was $6.6 million (recorded in 2024), while the average stood at $12.0 million.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 9267.44% in 2022, then skyrocketed by 858650.79% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Payables (Quarter) stood at $6.6 million in 2021, then fell by 25.13% to $4.9 million in 2022, then crashed by 56.32% to $2.2 million in 2023, then surged by 960.4% to $22.8 million in 2024, then soared by 117.89% to $49.8 million in 2025.
  • Its Payables stands at $49.8 million for Q3 2025, versus $44.3 million for Q2 2025 and $27.0 million for Q1 2025.